A critical analysis of studies assessing L-ornithine-L-aspartate (LOLA) in hepatic encephalopathy treatment

Arquivos de Gastroenterologia

Volumn 46, Issue 3, 2009, Pages 241-247

  De Soárez, Patrícia Coelho ^a   Oliveira, Ana Cláudia ^a   Padovan, Jorge ^a   Parise, Edison Roberto ^a   Ferraz, Marcos Bosi ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Dipeptides; Hepatic encephalopathy

Indexed keywords

ORNITHINE ASPARTATE; PLACEBO;

ARTICLE; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFICACY; DRUG WITHDRAWAL; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERAMMONEMIA; INFORMATION RETRIEVAL; MEDLINE; META ANALYSIS; NAUSEA AND VOMITING; PATIENT COMPLIANCE; SYSTEMATIC REVIEW;

AMMONIA; CLINICAL TRIALS AS TOPIC; DIPEPTIDES; DOUBLE-BLIND METHOD; EVIDENCE-BASED MEDICINE; HEPATIC ENCEPHALOPATHY; HUMANS;

EID: 70449623959     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/S0004-28032009000300019     Document Type: Article

References (73)

1. Albrecht J, Hilgier W, Januszewski S, Quack G. Contrasting effects of thioacetamide-induced liver damage on the brain uptake indices of ornithine, arginine and lysine: modulation by treatment with ornithine aspartate. Metab Brain Dis. 1996;11:229-237 (Pubitemid 126738977)
2. Aschke J. Experiences with ornithine-aspartate in liver diseases. Med Welt. 1969;22:657-662
3. Balestrieri C, De Cristofaro D, Cittadini D. Effect of ornithine-aspartate mixture on 15N-ammonia incorporation into urea in intact mice. Life Sci. 1967;6:337-340
4. Because hepatic encephalopathy is a frequent contributing factor. Patients with liver cirrhosis are poorer drivers. MMW Fortschr Med. 2003;145:61.
5. Butterworth RF. Pathophysiology of hepatic encephalopathy: a new look at ammonia. Metab Brain Dis. 2002;17:221-227 (Pubitemid 36204752)
6. Butterworth RF. Brain edema in acute liver failure. Indian J Gastroenterol. 2003;22(Suppl 2):s59-61.
7. Butterworth RF. Role of circulating neurotoxins in the pathogenesis of hepatic encephalopathy: potential for improvement following their removal by liver assist devices. Liver Int. 2003;23(Suppl 3):5-9.
8. Chen MF, Li RC, Chen CH, Gao XC. [Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy]. Di Yi Jun Yi Da Xue Xue Bao. 2005;25:718-9, 22.
9. Chronic liver diseases. Hepatic encephalopathy too frequently overlooked? MMW Fortschr Med. 2000;142:56-57
10. Cirrhotic liver gives up in breaking up of ammonia. Poison for the brain. MMW Fortschr Med. 2004;146:51.
11. Delcker A, Turowski B, Mihm U, Raab P, Rusch O, Pilatus U, et al. Proton MR spectroscopy of neurometabolites in hepatic encephalopathy during L-ornithine- L-aspartate treatment--results of a pilot study. Metab Brain Dis. 2002;17:103-111 (Pubitemid 34655049)
12. Desjardins P, Belanger M, Butterworth RF. Alterations in expression of genes coding for key astrocytic proteins in acute liver failure. J Neurosci Res. 2001;66:967-971
13. Eisenburg J. Hepatic minimal encephalopathy. The most frequently overlooked, clinically occult "metabolic syndrome" on the cirrhosis patient. Fortschr Med. 1996;114:141
14. Finsterer J, Bernauer E. Recovery from Parkinson syndrome and prolonged visually evoked potentials in hepatic encephalopathy. Metab Brain Dis. 2005;20:55-60.
15. Gebhardt R, Beckers G, Gaunitz F, Haupt W, Jonitza D, Klein S, Scheja L. Treatment of cirrhotic rats with L-ornithine-L-aspartate enhances urea synthesis and lowers serum ammonia levels. J Pharmacol Exp Ther. 1997;283:1-6. (Pubitemid 27438939)
16. Groeneweg M, Quero JC, De Bruijn I, Hartmann IJ, Essink-bot ML, Hop WC, Schalm SW. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology. 1998;28:45-49 (Pubitemid 28299984)
17. Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA. 1993;270:2598-2601
18. Hartung HD. Amino acids prevent hepatic encephalopathy. Ornithine-aspartate in hyperammonemia-results of a study. Fortschr Med. 1989;107:56.
19. Hass HG, Nagele T, Seeger U, Hosl F, Gregor M, Kaiser S. Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS). Z Gastroenterol. 2005;43:373-378
20. Henglein-Ottermann D. Influence of ornithine aspartate on the experimentally induced hyperammoniemia. Clinico-experimental study. Ther Ggw. 1976;115:1504-1518
21. Holm E, Hess Y, Leweling H, Barth H-O, Hagmüller E. Ornithine aspartate (OA) promotes amino acid (AA) retention in the peripheral tissues of patients with liver cirrhosis A double-blind randomized crossover study. JPEN J Parenter Enteral Nutr. 2000;15:368.
22. Hong Y, Yang ZB, Wang YF. Clinical control study of L-ornithine-L- aspartate in the treatment of subclinical hepatic encephalopathy. West China Med J. 2003;18:509-510
23. Hunold W. Clinical experiences in liver diseases (especially in patients with fatty liver due to alcoholism and food poisoning) under monotherapy with ornithine aspartate. Z Allgemeinmed. 1973;49:469-472
24. In liver cirrhosis, not every "ammonia lowering drug" improves neuropsychiatric deficit. MMW Fortschr Med. 2001;143(9):58.
25. Ito M, Matsumoto H, Kikuchi S, Yachi A. A comparative study of free amino acid levels in the serum and cerebral cortex in hepatic failure rats. No To Shinkei. 1986;38:63-68 (Pubitemid 16178723)
26. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
27. Jalan R, Seery JP, Taylor-Robinson SD. Review article. Pathogenesis and treatment of chronic hepatic encephalopathy. Aliment Pharmacol Ther. 1996;10:681-697
28. Jalan R. Intracranial hypertension in acute liver failure: pathophysiological basis of rational management. Semin Liver Dis. 2003;23:271-282 (Pubitemid 37052452)
29. Kircheis G, Metz M, Frey S, Seiller E. Correlation between pharmacokinetic aspects and clinical efficacy of L-ornithine-L-aspartate (OA): results of randomized, controlled clinical trials. J Hepatol. 1996;25(Suppl 1):s131.
30. Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Görtelmeyer R, Hendricks R, Krüger B, Kuklinski B, Meister H, Otto HJ, Rink C, Rösch W, Stauch S. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology. 1997;25:1351-1360 (Pubitemid 27250753)
31. Kircheis G, Haussinger D. Management of hepatic encephalopathy. J Gastroenterol Hepatol. 2002;17(Suppl 3):s260-7.
32. Kircheis G, Wettstein M, Dahl S, Haussinger D. Clinical efficacy of L-ornithine- L-aspartate in the management of hepatic encephalopathy. Metab Brain Dis. 2002;17:453-462 (Pubitemid 36204774)
33. Kleef R, Scheller A. L-ornithine aspartate - a rationale for its use in combination with chemotherapy, radiation, and hyperthermia in oncology. Forsch Komplementarmed. 1999;6:216. (Pubitemid 29459413)
34. Koczorek M. Chronic liver diseases. The nihilism has gone. MMW Fortschr Med. 2001;143(51/52):14.
35. Kosozu K. Clinical study on the effects of L-ornithine-L-aspartate on liver dysfunction. Iryo. 1966;20:339-346
36. Kowalski P, Bieniecki M. Pharmacokinetics and bioavailability study of L-ornithine- L-aspartate in healthy volunteers - a comparative study of two oral formulations. J Pharm Biomed Anal. 2006;41:1061-1064
37. Kowalski P, Bieniecki M, Oledzka I, Lamparczyk H. Validated method for L-ornithine-L-aspartate analysis in human plasma by capillary electrophoresis. Biomed Chromatogr. 2006;20:185-194 (Pubitemid 43230871)
38. Kruger B, Held C, Kircheis G. Ornithine aspartate in hepatic encephalopathy: an established new therapeutic approach. Overview and results of current randomized studies. Z Arztl Fortbild (Jena). 1994;88:673-679
39. Lang I, Feher J, Gogl A, Varga L, Varga L, Pronai L, Werling K. Ammonia-lowering effect of ornithine-aspartate infusion in cirrhotic patients with hepatic encephalopathy. Gut. 1994;35(Suppl 4):s158.
40. Leweling H, Gladisch R, Staedt U, Wolters U, Holm E. Effects of ornithine aspartate (OA) on plasma ammonia and plasma amino acids (AA) in patients with liver cirrhosis. A double-blind, randomized study using a four-fold crossover design. Hepatology. 1990;10(Suppl 1):s13.
41. Maev IV, V'Iuchnova E S, Lebedeva EG, Iakovenko EI, Dicheva DT. The response to combined therapy of hepatic encephalopathy in patients with hepatic cirrhosis. Klin Med (Mosk). 2002;80:42-45
42. Maneesh M, Jayalekshmi H. Effect of ascorbic acid, alpha-tocopherol, lecithin and L-ornithine-L-aspartate on ethanol induced hypoproteinemia and hyperlipidemia in rats. Indian J Physiol Pharmacol. 2005;49:422-426 (Pubitemid 41565801)
43. Melzer H, Weber D, Wotzka R. On the therapy of liver diseases with ornithine aspartate. Med Klin. 1969;64:1541-1544
44. Mullen KD. Newer aspects of hepatic encephalopathy. Indian J Gastroenterol. 2003;22(Suppl 2):s17-s20.
45. Nakamura H, Ishikawa M. Effect of ornithine-aspartate on fecal excretion of mevalonate metabolites and the reticuloendothelial system. Igaku To Seibutsugaku. 1971;83:213-215
46. Nilius R, Kircheis G. Improvement of hepatic encephalopathy (HE) in cirrhotic patients by treatment with L-ornithine-L-aspartate (OA) infusion concentrate. Results of a placebo-controlled, double-blind clinical trial. J Hepatol. 1992;16(Suppl 1):s39.
47. Ortiz M, Jacas C, Cordoba J. Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. J Hepatol. 2005;42(Suppl 1):s45-s53. (Pubitemid 40364603)
48. Perinovic M, Robovic Z, Grujic M, Ljubojevic S. Personal experiences in the treatment of internal diseases with ornithine aspartate. Med Arh. 1969;23(3):29-32.
49. Podymova SD, Bueverov AO, Nadinskaia M. The treatment of hepatic encephalopathy with Hepa-Mertz. Ter Arkh. 1995;67(6):45-47
50. Quero JC, Schalm SW. Subclinical hepatic encephalopathy. Semin Liver Dis. 1996;16:321-328
51. Quero Guillen JC, Carmona Soria I, García Montes JM, Jíménez Sáenz M, Herrerías Gutiérrez JM. Hepatic encephalopathy: nomenclature, pathogenesis and treatment. Rev Esp Enferm Dig. 2003;95:135-42, 127-134 (Pubitemid 36411084)
52. Raab W. Confirmation of a liver-protecting action of L-ornithine-L- aspartate using the experimental model of hypokalaemic liver damage. Wien Klin Wochenschr. 1972;84:348-349
53. Rees CJ, Oppong K, Al-Mardini H, Hudson M, Rose J. The effect of L-Ornithine- L-asparate on tips patients undergoing glutamine challenge. Eur J Gastroenterol Hepatol. 1996;8(Suppl 5):s16.
54. Rees CJ, Oppong K, Al Mardini H, Hudson M, Record CO. Effect of L-ornithine- L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial. Gut. 2000;47:571-574
55. Reynolds N, Downie S, Smith K, Kircheis G, Rennie MJ. Treatment with L-ornithine-L-aspartate (LOLA) infusion restores muscle protein synthesis responsiveness to feeding in patients with cirrhosis. J Hepatol. 1999;30(Suppl 1):65.
56. Romero Gomez M, Bautista JD, Grande L, Ramos Guerrero RM, Sanchez Munoz D. New concepts in the physiopathology of hepatic encephalopathy and therapeutic prospects. Gastroenterol Hepatol. 2004;27(Suppl 1):40-48
57. Rose C, Michalak A, Pannunzio P, Therrien G, Quack G, Kircheis G, Butterworth RF. L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action. Metab Brain Dis. 1998;13:147-157 (Pubitemid 28350749)
58. Rose C, Michalak A, Rao KV, Quack G, Kircheis G, Butterworth RF. L-ornithine- L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure. Hepatology. 1999;30:636-640 (Pubitemid 29409406)
59. Schafer W. Intravenous administration of ornithine aspartate to patients with hepatic diseases. Munch Med Wochenschr. 1968;110:2521-2525
60. Seki S. Study of the treatment of liver damage due to several causes in tuberculosis, using ornithine-aspartate. Iryo. 1966;20:354-363
61. Shioya A, Kuraishi K, Kakimoto M, Tamama Y. Pharmacological study on L-ornithine L-aspartate. Jpn J Pharmacol. 1964;14:201-214
62. Sommer H, Unglaub W. Influence of ornithine-aspartate on the increased GOT activity in bovine serum. Berl Munch Tierarztl Wochenschr. 1972;85:123-125
63. Staedt U, Leweling H, Gladisch R, Kortsik C, Hagmuller E, Holm E. Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design. J Hepatol. 1993;19:424-430 (Pubitemid 24029921)
64. Stauch S, Kircheis G, Adler G, Beckh K, Ditschuneit H, Görtelmeyer R, Hendricks R, Heuser A, Karoff C, Malfertheiner P, Mayer D, Rösch W, Steffens J. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol. 1998;28:856-864 (Pubitemid 28223491)
65. Strauven T, Mardens Y, Clara R, Terheggen H. Intravenous loading with arginine-hydrochloride and ornithine-aspartate in siblings of two families, presenting a familial neurological syndrome associated with cystinuria. Biomedicine. 1976;24: 191-199
66. Szirmai E. Our clinical experience with ornithine aspartate. Minerva Med. 1971;62:2376-2382
67. Tandon BN. Hepatic encephalopathy syndromes. Indian J Gastroenterol. 2003;22(Suppl 2):s4-s6.
68. Vogels BA, Karlsen OT, Mass MA, Bovee WM, Chamuleau RA. L-ornithine vs. L-ornithine-L-aspartate as a treatment for hyperammonemia-induced encephalopathy in rats. J Hepatol. 1997;26:174-182 (Pubitemid 27072619)
69. Wang Y. Researching progress on prognosis judgment of hepatic failure. Zhonghua Gan Zang Bing Za Zhi. 2002;10:471-473
70. Wein C, Koch H, Popp B, Oehler G, Schauder P. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology. 2004;39:739-745 (Pubitemid 38337653)
71. Weissenborn K, Tietge UJ, Bokemeyer M, Mohammadi B, Bode U, Manns MP, Caselitz M. Liver transplantation improves hepatic myelopathy: evidence by three cases. Gastroenterology. 2003;124:346-351 (Pubitemid 36169251)
72. Wettstein M, Haussinger D. Hepatic encephalopathy-therapy. Dtsch Med Wochenschr. 2003;128:2658-2660
73. Wotzka R, Weber D. Further clinical experiences with ornithine aspartate in liver diseases. Ther Ggw. 1972;111:400-412